420 with CNW — New Poll Suggests Florida Cannabis Ballot Measure Has Ample Bipartisan Support to Pass

A new survey reveals that Florida’s initiative to legalize marijuana, set to be on the ballot in November, has enough support to potentially pass, boasting majority approval across various demographic groups.

The poll, conducted by the University of North Florida (UNF), indicates that 64% of likely voters favor the marijuana reform proposal. This percentage exceeds the 60% threshold needed to amend the state constitution. The survey respondents were provided with the complete text of Amendment 3 as it will appear on the ballot.

The data shows that Democrats are the most supportive group, with 79% backing the initiative, independents at 63% with GOP supporters at 50%. Additionally, the poll reveals widespread support across different age and racial groups, as well as among both those who voted for President Joe Biden (78%) and Donald Trump (50%) in the 2020 election.

Polls on the Florida initiative have consistently shown that most people support it, even though not all of them have shown the necessary 60% of votes to pass. The most recent survey results, which were released less than four months before election day, give supporters of the proposal hope.

However, the current 64% support is three points lower than the figures reported by UNF in a previous poll. Michael Binder, a political science professor at UNF, noted that the effectiveness of the opposition’s efforts to reduce support remains uncertain.

The poll surveyed 774 voters in Florida between July 24–27, with a margin of error of ±4.6 percentage points. Another opposition group, Vote No On 3, recently conducted its poll, which also found 64% support for the reform.

Governor Ron DeSantis attacked Amendment 3 earlier this month, making inflated assertions about its possible implications, which Amendment 3’s proponents have refuted. He contended that the amendment would grant an unrestricted right to marijuana usage, implying that it would provide more protection than the First and Second Amendments’ guarantees of free speech and the right to bear arms. Furthermore, he falsely claimed that the majority of Colorado voters regretted legalizing marijuana, even though current polls show that the state’s citizens remain strongly in favor of the change.

POB Ventures, a consortium of cannabis companies, donated $100,000 to DeSantis’s political action committee, the Florida Freedom Fund, to aid in opposition to bills on abortion and marijuana. This donation significantly boosted the campaign’s funds, which had been modest at the start of July.

Patrick O’Brien, POB Ventures CEO, noted that he isn’t opposed to the legalization of cannabis for adult use in general. He did, however, voice concerns with the referendum initiative’s exact wording, which permits regulators to issue more licenses rather than requiring them to.

Questions about the motives behind the donation to DeSantis’s PAC are likely to persist, especially following a CBS News Miami report suggesting that unnamed hemp entities have pledged to support DeSantis’s fight against the cannabis legalization measure, promising a collective $5 million contribution to the state GOP party. This pledge comes after the governor vetoed a bill that could have drastically impacted the hemp market by banning most cannabinoid products.

Despite recent donations, the DeSantis campaign is still far behind the prolegalization campaign, Smart and Safe Florida, in terms of fundraising, with the latter having raised more than $60 million since 2022.

Meanwhile, a Fox News survey conducted last month found that two-thirds of Floridians are in favor of the marijuana proposal, with the measure receiving greater support than the governor. Across the political spectrum, the majority of respondents to the survey supported legalization.

The entire marijuana industry, including entities such as Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF), will be waiting with bated breath to see whether voters make Florida the latest state to legalize recreational marijuana in the country this November.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannaCon Midwest Cleveland Convention To Focus On The Local Community

Cannabis growers, traders, license holders, physicians, patients, regulatory authorities, capital investors, professionals, and enthusiasts are invited to attend the CannaCon Cleveland Conference at the Huntington Convention Center, Cleveland, on October 3-4, 2024. The venue of the event, the Huntington Convention Center is situated in the heart of downtown Cleveland, near the legendary Rock & Roll Hall of Fame and the International Women’s Air & Space Museum, among others.

The CannaCon event offers a robust platform for the local cannabis community, with two full days of innovation, learning, networking, and collaboration. Exhibitors from around the world will be pitching their latest products and services to a crowd of established investors and business experts in the cannabis industry. Newbies and startups gain important visibility by showcasing their unique products and services for the right target audience.

Local businesses will be there to connect with cannabis leaders and investors. Attendees will witness an impressive lineup of industry leaders presiding as guest speakers. They will share invaluable insights about current industry trends and discuss the critical issues of current cannabis trade.

These leaders will cover a number of engaging topics, offering the best path forward to the cannabis community. From harvest quality to understanding the best practices to comply with rules and regulations, attendees can get answers to their queries regarding cannabis cultivation and trade in Cleveland.

Several plush accommodations are available near the Huntington Convention Center for the attendees. CannaCon serves as a business as well as an educational experience. Attendees will discover a wealth of information, products, and valuable connections, from cultivation supplies, cannabis innovations, discoveries in genetics,  and a wide range of vendor retail displays, to important scientific, legal, financial, and marketing ideas. Don’t miss out on this rich event.

To learn more, please visit https://cnw.fm/YoTB3

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

NECANN’s Michigan Cannabis Convention Offers Unique Business Ideas for Cannabis Sector

Businesses, entrepreneurs, investors, educators, patients, advocates, and consumers are invited to attend the NECANN Michigan Cannabis Convention on September 20-21, 2024, in Grand Rapids. NECANN events are organized to meet the needs and provide collaborative opportunities for the local cannabis community. One of the biggest cannabis conventions in the country, NECANN events witness some of the most eminent dignitaries of the cannabis spectrum gracing the event floor.

Instead of hosting generic cannabis conventions, NECANN took a customized approach. As every region has its challenges, NECANN understands the specific requirements relevant to the area. They collaborate with local traders, growers, investors, sponsors, and industries, so that the regional cannabis community benefits as a whole and enjoys a higher ROI. Operational since 2014, the NECANN team ensures all industry leaders and companies attend the event, expanding business opportunities for local cannabis traders.

Investors can discover fresh and innovative talent at the event. Budding companies can showcase their products and services at the exhibition booths. Investors and cannabis traders can have one-on-one conversations and develop business ties. Attendees can gain insights into the latest trends, and get know-how on the latest industry products and services at the NECANN event.

Top industry leaders conduct speaker sessions where they will share their invaluable expertise. Attendees can gain immense knowledge about current cannabis markets, and can learn about the tips, resources, and tools required to design winning marketing strategies in a competitive cannabis landscape. Experts presiding over the discussion panels will discuss new trends and techniques for the cannabis market to help businesses drive higher ROI.

To know more, please visit https://cnw.fm/b1Vp1

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Alternative Diabetes and Obesity Treatments

  • Lexaria, a global innovator in drug delivery platforms, is exploring alternatives to traditional diabetes and obesity management through its patented DehydraTECH(TM) technology to potentially enhance oral ingestion vs. injection treatment of GLP-1 drugs
  • The company has made significant strides pairing their bioavailability enhancing DehydraTECH with glucagon-like peptide-1 (“GLP-1”) drugs used for treatment of diabetes and obesity
  • Projections are that by 2030 over 54.9 of Americans could have diabetes, and that by 2045 one in eight adults globally will be living with the condition

According to the International Diabetes Federation Diabetes Atlas of 2021, 10.5% of adults aged between 20 and 79 globally have diabetes. In addition, almost half of them are unaware that they are living with the condition. The Federation further projects that by 2045, one in eight adults in the world will be living with diabetes. This will represent approximately 783 million people, an increase of 46% from the current numbers (https://cnw.fm/QsqcW).

The figures in the United States are just as startling, with 38.4 million people of all ages, or 11.6% of the country’s population having diabetes, according to the Centers for Disease Control (“CDC”) (https://cnw.fm/dHQHL). Also, a Population Health Management report shows estimates that, by 2030, over 54.9 million Americans will have diabetes, representing a 54% increase between 2015 and 2030 (https://cnw.fm/2oSYS). These statistics have prompted organizations and societies to initiate and sustain conversations around diabetes and its management.

They have also pushed organizations to explore ways to manage the condition better, and one that has stood out is Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms. Lexaria looks to offer a better alternative to diabetes management and treatment through its patented DehydraTECH(TM) technology. Testing conducted since 2016, has demonstrated the technology’s ability to increase bio-absorption. It has even evidenced an ability to deliver some drugs more effectively across the blood-brain barrier, with its range of applications scaling across bioactive molecules, oral cannabinoids, and other active pharmaceutical ingredients (“APIs”).

Lexaria has recently made strides with glucagon-like peptide-1 (“GLP-1”) studies. It has reported positive interim results from an animal study on diabetes. This milestone best showcases the potential of its patented technology in not only addressing diabetes and obesity. In the last month, the company announced the dosing completion of its human pilot study #2, GLP-1-H24-2, which sought to explore effective oral delivery of GLP-1 drugs. Some evaluated aspects included side effects, blood levels of semaglutide, the GLP-1 drug used in the study, and tolerability. The study also measured blood glucose and insulin levels, ultimately serving as an indicator in the potential treatment of diabetes and weight loss (https://cnw.fm/U3UGj).

GLP-1 drugs have been lauded for their potential to treat diabetes. However, when consumed orally, the stomach’s acidic environment seriously degrades its bioavailability, resulting in meager blood absorption rates of less than 1%, which is far from ideal. This has restricted their administration to painful injections, which can be a deterrent to some people.

“Most GLP-1 drugs sold today are administered by painful and expensive injection devices. More effective and tolerable oral delivery of GLP-1 drugs could be extremely valuable to patients and to industry,” noted Chris Bunka, Lexaria’s CEO (https://cnw.fm/C1osG).

With Lexaria’s DehydraTECH technology, increased bioavailability has been evidenced, bringing the company closer to offering a viable alternative to injectable delivery of GLP-1 drugs. In addition, the studies conducted so far have shown better tolerability of the GLP-1 drugs used, mainly Rybelsus(R), further pointing to the technology’s superiority and highlighting its potential in treating weight loss and diabetes.

Lexaria recognizes a market opportunity with its technology. It also recognizes a growing problem that needs to be addressed sooner rather than later. For a market valued at $79.3 billion in 2023, the company looks to create significant additional value for its shareholders (https://cnw.fm/WWCjR). As it continues with its GLP-1 studies, its management is optimistic about their outcome.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Legalizing Medical Cannabis in North Carolina Still Faces Huge Hurdles

For the third year in a row, the senate of North Carolina approved the Compassionate Care Act. The measure aims to allow the sale of marijuana and marijuana-infused products to patients who qualify under a set of strict conditions, utilizing a regulated medical marijuana system. Despite this progress, the legislation is presently stuck in the house.

Adding to the complexity, a recent decision by the Supreme Court has influenced the discussion around reclassifying marijuana as a Schedule 3 drug. Changing its classification from Schedule 1 to Schedule 3 would formally recognize its medical use, representing a small yet significant step toward legalization in North Carolina.

Earlier this year, the Eastern Band of Cherokee Indians launched the state’s first dispensary for medical cannabis, sparking renewed hope among Charlotte’s hemp entrepreneurs for the broader acceptance of medical cannabis. However, the dispensary operates outside of state law because of the tribe’s sovereign status.

According to Natacha Andrews, National Association of Black Cannabis Lawyers CEO, a majority of North Carolinians support the legalization of medical cannabis, despite a “stigma wall” that some legislators and residents still hide behind. Andrews pointed out that more than 80% of respondents in polls have expressed support for medical cannabis. However, some individuals self-exclude from the conversation due to long-standing beliefs instilled by their upbringing, religious teachings or societal norms that associate cannabis with negative connotations.

The proposed legislation is designed to aid individuals dealing with severe medical conditions such as PTSD, cancer and epilepsy. It has garnered bipartisan backing in the state legislature, including support from Republican Senator Bill Rabon, who has openly credited cannabis with aiding his recovery from colon cancer.

Conversely, Senator Jim Burgin, another Republican, argued that cannabis is not a recognized medicine, pointing out its lack of FDA approval and its current status as a controlled substance. Even if marijuana were to receive federal approval, Burgin stated that he would advocate for restricted forms of administration, such as suppositories, drops or nebulizers, as alternatives to smoking.

Financial projections suggest that legalizing medical marijuana in North Carolina could generate more than $15 million in the first year through application fees and a 10% tax on gross sales. However, Burgin contended that financial gain should not be the driving force behind legalization, especially if the primary goal is to address health issues and support those suffering from conditions such as PTSD.

Andrews believes that the question isn’t if marijuana will become legal in North Carolina, but when. She urges residents and businesses to prepare for the inevitable legalization as societal perceptions and global attitudes toward cannabis continue to shift.

Currently, the bill remains stuck in the house, with Speaker Tim Moore stating that they need 37 Republican votes to bring the bill to the floor. They have yet to secure the necessary support. Marijuana industry players, including major enterprises such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF), will be hoping that the legislators in the state soon find a way to give patients an option of trying medical marijuana as an alternative or complement to the conventional medications they take to combat the diseases afflicting them.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

InMed Pharmaceuticals Inc. (NASDAQ: INM) Subsidiary BayMedica Releases Market Report for 2023 on “Minor Cannabinoids”

  • The report explores the growth, competition, and consumer trends, for lesser known cannabinoids
  • The report highlights a 5.4% revenue increase in the edible market for 2023, with total sales reaching $2.097 billion
  • As consumer preferences shift towards edibles for their therapeutic effects and consistent experiences, the industry product landscape is set to evolve

With the increasing acceptance of cannabis use in society, the popularity of edibles—products containing cannabinoids that can be consumed as food or drink—has surged. While many consumers are familiar with edibles containing THC (tetrahydrocannabinol), known for its euphoric effects, or CBD (cannabidiol), recognized for its therapeutic benefits, there is a growing interest in edibles infused with non-intoxicating minor cannabinoids. These lesser-known cannabinoids offer unique properties and potential health benefits, driving significant market growth.

BayMedica, a subsidiary of InMed Pharmaceuticals (NASDAQ: INM), specializes in rare cannabinoids, and has published a report on the expansion of the minor cannabinoid market in 2023. Link to a full copy of the report can be found at https://cnw.fm/G09iZ.

The report, based on data from Headset, the largest industry dataset, explores the growth, competition, and consumer trends in ten regulated states, encompassing 85 million of the 158 million residents in areas where recreational cannabis is legal (https://cnw.fm/4bUnm).

The report highlights a 5.4% revenue increase in the edible market for 2023, with total sales reaching $2.097 billion. This growth is attributed to innovative developments in minor cannabinoid products. Among edible products, gummies demonstrated robust sales, while minor cannabinoid-infused edibles experienced an impressive 47% year-over-year growth, totaling $391 million in sales.

Despite a decrease in the average price of edible items from $14.29 to $12.54, the strong consumer demand and reduced production costs have made minor cannabinoids a strategic focus for brands aiming to secure a competitive position in the industry.

Minor cannabinoids, although less prominent than THC and CBD, are gaining attention for their distinctive properties and potential health benefits. These compounds, found in smaller quantities in cannabis plants, are transforming the cannabinoid landscape. Key minor cannabinoids include:

  • Cannabichromene (“CBC”): Known for enhancing the body’s natural endocannabinoid, anandamide, by prolonging its presence in the bloodstream
  • Tetrahydrocannabivarin (“THCV”): Non-psychoactive, it may suppress appetite and enhance focus and energy
  • Cannabidivarin (“CBDV”): Similar to CBD, it potentially supports brain, immune, and gut health
  • Cannabinol (“CBN”): Mildly psychoactive, known for its sedative and antibacterial properties, beneficial for insomnia and pain relief

The endocannabinoid system (“ECS”), discovered in the late 1980s, plays a crucial role in regulating various body functions. Every cell type has cannabinoid receptors that interact with over 140 known cannabinoids. The ECS’s therapeutic potential spans numerous diseases, though extracting minor cannabinoids is challenging due to their low quantities and the high cost of separation. BayMedica’s advancements in biosynthesis and synthetic chemistry now allow for commercial-scale production, opening new therapeutic avenues.

In 2023, nearly half of the top 50 selling edibles contained minor cannabinoids, reflecting a significant market trend. Leading brands are innovating with formulations that appeal to a diverse consumer base, allowing them to command premium pricing for minor cannabinoid products. These products have a 6.3% higher average price and a 73% higher average EQ (Equivalent) price compared to THC-only products, indicating a strong consumer willingness to pay for added benefits. The entourage effect theory suggests that combining minor cannabinoids with major cannabinoids like THC and CBD enhances medicinal benefits, such as pain relief.

Commercial adoption of minor cannabinoids in edibles provides insights into consumer preferences. CBN has emerged as a leader in sales, likely due to its sedative effects. CBG, while currently strong, may see a future decline as other minor cannabinoids gain traction. CBC and THCV have shown significant sales growth in 2023, driven by research into their potential benefits and increased production efficiency.

As consumer preferences shift towards edibles for their therapeutic effects and consistent experiences, the cannabis product landscape is set to evolve. Brands must align with these changing needs, emphasizing minor cannabinoids for holistic well-being. BayMedica remains committed to scaling operations and expanding product offerings to meet the rising demand for high-quality cannabinoids, supporting a broad and growing customer base.

For more information, visit the company’s website at www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — CU Anschutz Researchers Studying Users’ Capacity to Drive Under Influence of Marijuana

Researchers at the CU Anschutz School of Public Health have embarked on a paid study focusing on marijuana users to examine impairment levels. Over the past two years, the research has involved more than 200 participants aged between 25 and 55 years. Depending on the amount of marijuana consumed, each study session can last anywhere from three to five hours.

Dr. Ashley Brooks-Russell, a lead researcher at the school, explained, “This study allows us to observe the changes people experience after consuming cannabis, including alterations in driving behavior, reaction times, memory, blood composition and eye characteristics. Police officers, in particular, often examine eye changes as a sign of impairment during traffic stops.”

Brooks-Russell highlighted that cannabis impairment remains a significant issue, contributing to crashes and traffic stops. Unlike other drugs, detecting marijuana impairment is challenging due to the lack of straightforward tools for law enforcement. “We’re particularly interested in how daily cannabis users differ from occasional users. Many people use cannabis for medical reasons and develop tolerance, showing fewer changes compared to those who use it sporadically,” she added.

Participants are placed in a controlled environment during the study, where they consume high-concentration marijuana products such as edibles, dabs or vape pens. Once the substance takes effect, researchers conduct blood tests, administer various assessments on an iPad and evaluate participants’ driving abilities using a simulator. The driving simulator is not designed to measure one’s driving skill but rather to observe any negative changes in driving ability due to cannabis use.

The researchers have observed subtle driving impairments among occasional recreational marijuana users, such as weaving in traffic, delayed reaction times, memory lapses and eye changes.

“Our focus is currently on cannabis alone, but there’s potential to expand the study to include cannabis in combination with other substances. In real-world scenarios, people often use multiple substances that affect different brain parts, leading to varied effects. Understanding these interactions is crucial,” noted Dr. Brooks-Russell.

Additionally, the study aims to involve adults 65 years of age and older, because this demographic is experiencing the fastest growth in cannabis use. “In this age group, there are added complexities, like other medications they may be taking and normal cognitive decline associated with aging,” Brooks-Russell explained.

Ultimately, this research aims to develop a tool, similar to an alcohol breathalyzer, which could assist law enforcement in accurately detecting cannabis impairment and enhancing road safety. The entire cannabis industry, including established companies, such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED), is likely to take an interest in this ongoing study and any actionable outcomes that may result upon its conclusion.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Study Says Medical Marijuana Legalization Increases Parenting Time, Boosts Child Development

A recent study indicates that the availability of medical cannabis might lead to increased parenting time by improving patients’ overall health. Published in the “Journal of Applied Economics,” the research notes that medical cannabis legalization enhances sleep and reduces inactivity, aligning with its health benefits.

According to the study, the legalization of medical cannabis can have a positive effect on a child’s development by allowing parents to spend more time with their kids, particularly if they are younger than six years old, a critical age for parental involvement. These advantages, however, are dependent on parents not abusing cannabis.

Legalizing medical marijuana, according to the researchers, results in more time spent with children. This is seen in both passive childcare, where parents watch over their children while working on other tasks, and active childcare, where parents play with their kids. Parents who are likely to benefit from medical marijuana and have greater parenting experience overall — especially those with small children — have more significant impacts from the drug.

The study’s data came from the American Time Use Survey (ATUS) conducted by the United States Bureau of Labor Statistics between 2003 and 2019. Participants in the ATUS recorded their daily activities every 15 minutes.

To measure the increase in parenting time, the researchers compared education levels between groups. Parents with some college education generally spent more time on active parenting than those with less education. The educational difference was reflected by a four-minute increase (12.56%) in active childcare and a ten-minute increase in passive childcare, accounting for 8.92% of the difference.

Nonworking parents spend more time on active childcare than working parents, with the study showing a 22-minute difference. The difference in childcare costs between working and nonworking parents can be attributed to treatment effects on active childcare (18%) and passive childcare (7%).

Parents with children under six years of age as well as those on weekends showed greater increases in parenting time. The report highlights that the increases are focused on activities such as playing with and looking after children, with no significant effect on more demanding tasks such as planning or organizing for children.

One argument is that medicinal marijuana facilitates the management of pain and other ailments, allowing parents to spend more time with their kids doing less physically demanding activities. This is consistent with the use of medical marijuana to treat depression, anxiety, insomnia and chronic pain.

Interestingly, men showed a greater increase in parenting time post-legalization compared to women, which aligns with previous research indicating men’s higher increase in marijuana use following legalization. Moreover, the effect was more pronounced in states with higher religious activity.

The study found no evidence that medical cannabis legalization negatively impacted productive time use, such as home production and market work, or led to increased tobacco or drug use.

However, a key drawback of the study is the lack of individual-level cannabis use data in the ATUS. “Moreover, it is imperative to interpret the results in light of the USA’s global leadership in the consumption of opioid analgesics, which could serve as a viable alternative to medical cannabis,” the authors noted.

The findings of this study are likely to provide some additional validation for numerous companies such as Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) that are engaged in commercializing medical marijuana products that target different health conditions, such as chronic pain.

NOTE TO INVESTORS: The latest news and updates relating to Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) are available in the company’s newsroom at https://cnw.fm/SFWJ

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Nearly 43,000 Comments Sent to the DEA; Highlights Shared Here

The public comment period for the U.S. Drug Enforcement Administration’s (DEA) proposed marijuana rescheduling rules recently ended, and now the agency will analyze the responses, marking the first time they are considering public opinions on cannabis. Approximately 43,000 comments were submitted by individuals, researchers and organizations, making it the highest number of responses the DEA has ever received for a proposed regulation change.

The drug markets and legal regulation director at the Drug Policy Alliance, Cat Packer, highlighted that the huge response demonstrates the public’s great interest in cannabis legalization in the United States.

People used this opportunity to share their opinions and personal experiences on marijuana usage and legalization, in addition to talking about the proposed policy. Some raised worries that minors could be harmed by cannabis rescheduling or that it acts as a gateway drug. On the other hand, many people talked about their positive experiences and mentioned how cannabis helped with ailments including autism, anxiety and seizures.

According to a preliminary review, the majority of commenters felt that rescheduling was insufficient and demanded larger measures toward federal legalization. The DEA’s proposal aims to reclassify marijuana from Schedule 1 to 3, which would recognize it as a medication eligible for approval by the U.S. Food and Drug Administration (FDA), though it would remain federally illegal in most situations.

Packer drew attention to the fact that the discrepancy between federal and state laws is not resolved by rescheduling. Moreover, it doesn’t address the past racial injustices associated with the criminalization of cannabis or the racial inequities that followed.

Packer’s viewpoint is reflected in the majority of responses, many of which call for complete legalization. After doing a keyword analysis on the comments, the Drug Policy Alliance discovered that 59% of respondents wanted cannabis to be treated the same as tobacco or alcohol and completely descheduled, or decriminalized.

The comments were also examined by Headset, a marijuana data platform, utilizing the most recent iteration of OpenAI’s language model. An estimated 57% of comments supported descheduling cannabis, while 35% supported rescheduling and 8% wanted marijuana to stay classified as a Schedule 1 drug, according to the analysis. These findings are consistent with a Pew study that found 32% of Americans think cannabis should only be allowed for medical use, while 57% of Americans say it should be allowed for both recreational and medical usage.

The AI analysis provided additional insights, such as a pattern where opposition to medical cannabis came in waves of form letters, whereas support for legalization appeared more organically. Packer hypothesized that those making comments would be swayed by President Joseph Biden’s prior remarks regarding the legalization of cannabis, particularly his pledge to decriminalize it during the 2020 campaign.

The next steps in the process are uncertain as the DEA navigates this unprecedented situation. CEO and cofounder of the National Cannabis Industry Association, Aaron Smith, stated that although he sees rescheduling as a step in the right direction and hopes it happens before year’s end, he understands that the DEA is unlikely to completely deschedule cannabis based only on public sentiment.

Packer, meanwhile, had doubts regarding the schedule, speculating that several circumstances would cause the procedure to be postponed until after the next presidential election or possibly until the conclusion of Biden’s term. In addition, the DEA could be forced to postpone its decision indefinitely if it is sued or has a public hearing. Packer stressed that federally criminalizing marijuana will still have negative consequences, even if the rescheduling goes on.

Smith also questioned how the DEA would handle the relatively low support for rescheduling alone. She noted that if the DEA proceeds with making cannabis a Schedule 3 substance, only 35% of those who commented would be satisfied, potentially leaving a significant portion of the public disappointed.

Stakeholders such as Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) will be waiting to see how this rescheduling pans out and when the final rule is published.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Software Effective Solutions Corp. (SFWJ) Dedicated to Becoming Leader in Growing Cannabis Sector

  • A recent report projects that the cannabis market, which totaled an estimated $27.7 billion in 2022, will reach $82.3 billion by 2027
  • The forecast includes businesses and enterprises involved in the cultivation, processing, distribution and sale of cannabis and cannabis-related products
  • MedCana is building technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world

With the worldwide cannabis market projected to see a compound annual growth rate (“CAGR”) of 24.3% in the next three years, Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ) is committed to strengthening its foothold in the growing space. The company, which is committed to being a global force for better cannabis products, is determined to be the world’s premier resource for pharmaceutical cannabis products.

“The cannabis market is estimated at $27.7 billion in 2022 and is projected to reach $82.3 billion by 2027, at a CAGR of 24.3%,” reported a MarketsandMarkets article earlier this year (https://cnw.fm/NorFm). “In recent years, the cannabis industry has experienced significant growth and expansion, driven by increasing legalization efforts in various parts of the world, shifting public attitudes towards cannabis use and recognition of its potential medicinal benefits. This growth has led to the emergence of a diverse range of companies, including large-scale producers, dispensaries, manufacturers of cannabis-derived pharmaceuticals, technology firms developing innovative cultivation and extraction methods, and ancillary businesses providing services such as packaging, branding, and legal support.”

Noting that the term “cannabis industry” refers to the collection of businesses and enterprises involved in the cultivation, processing, distribution and sale of cannabis and cannabis-related products, the article outlines several factors likely to contribute to the sector’s growth, including legalization efforts, product innovation, investment and M&A activity, and the regulatory landscape.

The article also noted that “the medical cannabis segment is expected to continue growing, driven by increasing recognition of cannabis’s therapeutic properties and its potential to treat various medical conditions. Pharmaceutical companies are also investing in cannabis-based medications, contributing to market expansion.” In addition, “The recreational cannabis market is [also] forecasted to see continued growth, particularly in regions where legalization has occurred or is expected. Changing attitudes towards cannabis use and increasing consumer acceptance are key drivers in this segment.”

These factors all point to a promising cannabis sector moving forward, with MedCana committed to doing the work necessary to become a leader in the space. The company is building the technology, laboratories, growing facilities and scientific teams needed to provide premium pharmaceutical-grade cannabis extracts to the world, all with absolute integrity, sustainability and social responsibility (https://cnw.fm/D4Au8).

MedCana is a global infrastructure and holding company in the cannabis industry. The company currently has five divisions focused on pharmaceutical cannabis production, as well a software division focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology division has rounded out MedCana’s portfolio of holdings.

For more information, visit the company’s website at www.MedCana.net.

NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://cnw.fm/SFWJ

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN